Protamine Dosing for Heparin Reversal after Cardiopulmonary Bypass: A Double-blinded Prospective Randomized Control...

Area of Science:

• Cardiology
• Anesthesiology
• Pharmacology

Background:

• Drug shortages pose clinical challenges, particularly for essential medications like protamine.
• Conventional protamine dosing based on heparin ratios can lead to overuse and potential harm.
• This study investigated an alternative fixed-dose protamine strategy to address these concerns.

Purpose of the Study:

• To compare the efficacy of a fixed 250-mg protamine dose versus a standard 1:1 heparin ratio-based dose for heparin reversal.
• To assess if a fixed protamine dose can reduce overall protamine utilization.
• To evaluate the impact on activated clotting time and postoperative bleeding.

Main Methods:

• A single-center, double-blinded randomized trial involving adult cardiac surgical patients.
• Patients received either a fixed 250-mg protamine dose or a ratio-based dose (1 mg:100 U heparin) after cardiopulmonary bypass.
• Primary outcome was post-protamine activated clotting time; secondary outcomes included total protamine dose and chest tube output.

Main Results:

• No significant difference in postprotamine activated clotting time between the fixed-dose and ratio-based groups (P = 0.47).
• Significantly less total protamine was administered in the fixed-dose group (P < 0.0001).
• No difference in 24-h chest tube output between the groups (P = 0.28).

Conclusions:

• A fixed 250-mg protamine dose is as effective as the standard heparin ratio-based strategy in achieving adequate heparin reversal.
• The fixed-dose strategy significantly reduces protamine consumption.
• This approach offers a viable option for conserving protamine and mitigating drug shortages without compromising patient safety or outcomes.